Democrats say Trump increased investments in drugmakers that were given Medicare exemptions

The congressional Democrats' report examined how Trump's pharmaceutical investments changed after he returned to the White House. It found a sharp increase in the reported value of his holdings. Democrats connected part of that growth to companies benefiting from exemptions in Medicare's drug price negotiation program.

Trump's pharmaceutical stock holdings rose from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. Up to $39.1 million was held in companies benefiting from exemptions created or expanded by the 2025 Republican tax and spending law.

The report also identified purchases before Trump signed the law. His portfolio bought as much as $2.55 million in shares of companies receiving exemptions, including up to $950,000 on July 1, 2025. The White House denied conflicts, saying outside institutions independently manage the portfolio.

Medicare drug price negotiation is a federal program that allows Medicare to negotiate prices for certain expensive prescription medicines. The article says President Joe Biden's administration created this authority for the first time, covering some of the costliest drugs. Negotiated prices can reduce what Medicare and its beneficiaries pay.

The program can affect drugs selected among high-cost prescription medicines. The article names Keytruda, made by Merck, and Opdivo, made by Bristol Myers Squibb, as cancer drugs whose prices could be affected. It also explains that rare-disease exemptions can delay or prevent some medicines from entering negotiations.

The program remains central to the dispute because exemptions narrow its reach. Supporters of broader exemptions say they encourage rare-disease research. Critics say companies can use them to protect blockbuster medicines from price reductions. The article does not provide a complete list of eligible drugs.

The scale of the reported increase was substantial. Trump's pharmaceutical stock holdings had a maximum reported value of $1.7 million in 2024. By the end of 2025, that maximum had reached $56.2 million, according to the congressional Democrats' report.

The report estimated that up to $39.1 million of the 2025 holdings was in companies benefiting from exemptions to Medicare's drug price negotiation program. Those exemptions came through a provision in the Republicans' 2025 tax and spending law. The figures describe maximum reported values, not necessarily a single fixed amount.

Democrats also examined the timing of purchases. Trump's portfolio bought as much as $2.55 million in shares of companies benefiting from the exemptions on three dates before he signed the legislation. It later bought as much as $1 million in AbbVie stock in August 2025, after the law took effect.

The orphan drug exclusion is an exemption for medicines developed to treat rare diseases or conditions. It can delay when those drugs become eligible for Medicare price negotiations or exclude them entirely. The provision matters because negotiated prices might otherwise reduce what Medicare pays for some costly medicines.

Republicans expanded the existing exemption in their 2025 tax and spending law. Supporters argued that a broader exemption would encourage pharmaceutical companies to invest in treatments for rare diseases. The policy therefore uses protection from price negotiation as an incentive for research and development.

Critics see a different effect. They say the exemption can let makers of blockbuster medicines avoid negotiations that could lower costs for Medicare and its recipients. The article reports that the change may leave beneficiaries paying more for certain cancer treatments and other drugs, showing the tension between innovation incentives and affordability.

Exemptions can raise patients' costs by preventing Medicare from bargaining for lower prices. The congressional Democrats' report said some Medicare beneficiaries could pay thousands of dollars more for certain cancer treatments and other medicines. The added expense matters especially for people who depend on costly drugs over long periods.

The report estimated that beneficiaries receiving Keytruda, made by Merck, and Opdivo, made by Bristol Myers Squibb, could pay roughly $5,000 more. These medicines are examples of expensive cancer treatments that could lose the benefit of Medicare negotiation when exemption rules apply.

The broader consequence depends on which drugs qualify and how prices are set. Supporters argue exemptions protect incentives to develop rare-disease treatments. Critics argue they allow blockbuster medicines to retain high prices. The article presents the cost estimate as a warning about the policy's possible impact, not as a bill for every patient.

A blind trust normally places a president's assets under an independent trustee who controls investments without the president knowing the holdings or directing trades. This separation is intended to reduce conflicts between public decisions and private financial interests. That general explanation comes from established financial ethics practice, not from details in the article.

The article says Trump's stock and bond portfolio is independently managed by third-party financial institutions. White House spokesperson Davis Ingle said neither Trump nor family members can direct, influence, or provide input on investments or trading decisions. The arrangement is therefore presented as a barrier to direct control.

The article does not call Trump's portfolio a blind trust or describe whether he is unaware of every holding. That distinction matters because independent management and a formal blind trust are not automatically identical. Democrats still raised concerns because investments grew in companies benefiting from administration-linked policy, while the White House denied any conflict.

Medicare's bargaining power can lower prices because it represents many patients and purchases large amounts of medicine. Negotiation gives the program leverage to seek a lower price instead of accepting a drugmaker's initial charge. The article says Biden's administration allowed Medicare to negotiate for some of the costliest prescription drugs.

Lower prices can reduce spending for Medicare and beneficiaries. But exemptions remove some medicines from that bargaining process. The article says critics believe this protects blockbuster drugs from negotiations, while supporters argue broader exemptions encourage companies to develop treatments for rare diseases and conditions.

That creates a policy trade-off. Wider negotiation may improve affordability for people using expensive medicines, including some cancer treatments. Wider exemptions may preserve incentives for research into rare diseases, but could leave patients paying more. The article does not settle which effect is larger; it presents both sides of the debate over the 2025 law.